These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 1740680)

  • 1. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
    Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
    J Clin Oncol; 1992 Mar; 10(3):406-13. PubMed ID: 1740680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
    Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
    Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
    Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
    J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
    Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
    Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
    Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
    Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
    J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
    Heinemann V; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
    Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
    Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
    Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography.
    Nishi R; Yamauchi T; Ueda T
    Cancer Sci; 2006 Nov; 97(11):1274-8. PubMed ID: 17034368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
    Garcia-Cremades M; Melillo N; Troconiz IF; Magni P
    Clin Transl Sci; 2020 May; 13(3):608-617. PubMed ID: 32043298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
    Buesa JM; Losa R; Fernández A; Sierra M; Esteban E; Díaz A; López-Pousa A; Fra J
    Cancer; 2004 Nov; 101(10):2261-9. PubMed ID: 15484216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
    Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman AJ; Nowak BJ; Hertel LW; Plunkett W
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):61-7. PubMed ID: 7481847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
    van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
    Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.
    Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR
    Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
    Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
    Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
    Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
    Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.